| Variables |
|
Males
33 (67.3%) |
Females
16 (32.7%) |
Total
49 |
p value# |
| Number of clinical adverse events |
1 |
28 (84.8%) |
10 (71.4%) |
38 |
.419* |
| >1 |
5 (15.2%) |
4 (28.6%) |
9 |
| Occurrence of clinical adverse events |
No |
0 (0%) |
2 (12.5%) |
2 |
.102† |
| Yes |
33 (100%) |
14 (87.5%) |
47 |
| Occurrence of laboratory adverse events |
No |
32 (97.0%) |
16 (100%) |
48 |
.673† |
| Yes |
1 (3.0%) |
0 (0%) |
1 |
| GAGS T1 |
5 (0-25) |
2 (0-25) |
5 (0-25) |
876* |
| AQoL T1 |
93 (15-120) |
92 (20-120) |
92 (15-120) |
393* |
| GAGS% improvement |
47.7%
(15.9%-93.2%) |
51.1%
(9.1%-81.8%) |
50.0%
(9.1%-93.2%) |
429* |
| AQoL% improvement |
30.0%
(7.0%-78.0%) |
33.0%
(3.0%-94.0%) |
30.0%
(3.0%-94.0%) |
337* |
| # p value<0.05; *Mann-Whitney U test for quantitative variables; †Fisher test for qualitative variables; GAGS: global acne grading system; AQoL: acne quality of life. |
